Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "Shilpa-Medicare-Ltd"

10 News Found

Shilpa Medicare Unit IV, Jadcherla has cleared TGA, Australia GMP inspection
Drug Approval | October 18, 2023

Shilpa Medicare Unit IV, Jadcherla has cleared TGA, Australia GMP inspection

This inspection is the fourth major regulatory inspection (after Russia, Canada and Brazil), cleared by this site in the past two years


Shilpa Medicare receives UK MHRA approval for mouth-dissolving strips to treat illnesses
News | September 03, 2023

Shilpa Medicare receives UK MHRA approval for mouth-dissolving strips to treat illnesses

This approval has come from the company's finished dosage form manufacturing facility


Shilpa Medicare receives USFDA approval for Psoriatic Arthritis Drug
Drug Approval | April 11, 2023

Shilpa Medicare receives USFDA approval for Psoriatic Arthritis Drug

Apremilast Tablets, 10 mg, 20 mg, and 30 mg is a generic equivalent of reference listed drug (RLD) OTEZLA of Celgene.


Shilpa Medicare introduces cancer drug Capecitabine 1000 MG dispersible tablet
News | December 19, 2022

Shilpa Medicare introduces cancer drug Capecitabine 1000 MG dispersible tablet

The product is backed by required scientific proof and comparative bioequivalence studies


Briefs: Piramal Enterprises and Shilpa Medicare
News | December 02, 2022

Briefs: Piramal Enterprises and Shilpa Medicare

Shilpa Medicare Ltd's finished dosage form manufacturing facility, Unit IV, situated at Pharma SEZ, Jadcherla, Telangana has received Health Canada GMP approval


Shilpa Medicare receives tentative approval for Tenofovir Alafenamide Tablets
Drug Approval | September 22, 2022

Shilpa Medicare receives tentative approval for Tenofovir Alafenamide Tablets

The ANDA was filed as 'First to File' submission on NCE-1 date.


Shilpa Medicare completes clinical studies of high concentration biosimilar Adalimumab
Diagnostic Center | August 20, 2022

Shilpa Medicare completes clinical studies of high concentration biosimilar Adalimumab

The drug is expected to cater to the fast growing Rheumatoid Arthritis, Plaque Psoriasis, JIA, Psoriatic Arthritis, Ankylosing Spondylitis, Ulcerative Colitis, Crohns disease, HS and Uveitis markets


Shilpa Medicare launches dissolving oral thin films of Paracetamol
News | June 23, 2021

Shilpa Medicare launches dissolving oral thin films of Paracetamol

Shilpa's Paracetamol oral thin films are patent protected and are first of this kind in the world


Shilpa Medicare Jadcherla facility gets GMP certification from Russia
Policy | May 29, 2021

Shilpa Medicare Jadcherla facility gets GMP certification from Russia

The GMP certificate is valid for three years until April 2024.


Shilpa Medicare to produce 50 mn doses of Sputnik V Vaccine
News | May 18, 2021

Shilpa Medicare to produce 50 mn doses of Sputnik V Vaccine

Targeted production of the dual vector Sputnik V for the first 12 months is 50 million doses from the date of start of commercial production